Inventiva (IVA) Competitors $3.29 +0.03 (+0.80%) As of 07/18/2025 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALTShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Its Competitors Harrow Phibro Animal Health AbCellera Biologics Cogent Biosciences Pharvaris Intellia Therapeutics CureVac Aurinia Pharmaceuticals WAVE Life Sciences Calliditas Therapeutics AB (publ) Inventiva (NASDAQ:IVA) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations. Which has stronger earnings and valuation, IVA or HROW? Harrow has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M31.59-$199.34MN/AN/AHarrow$199.61M6.60-$17.48M-$0.56-64.09 Is IVA or HROW more profitable? Inventiva has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Inventiva's return on equity of 0.00% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Harrow -10.19%-25.01%-4.27% Do analysts rate IVA or HROW? Inventiva presently has a consensus price target of $10.40, indicating a potential upside of 216.49%. Harrow has a consensus price target of $63.83, indicating a potential upside of 77.86%. Given Inventiva's higher probable upside, analysts clearly believe Inventiva is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in IVA or HROW? 19.1% of Inventiva shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 13.7% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, IVA or HROW? Inventiva has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Does the media favor IVA or HROW? In the previous week, Harrow had 18 more articles in the media than Inventiva. MarketBeat recorded 18 mentions for Harrow and 0 mentions for Inventiva. Harrow's average media sentiment score of 0.45 beat Inventiva's score of 0.00 indicating that Harrow is being referred to more favorably in the news media. Company Overall Sentiment Inventiva Neutral Harrow Neutral SummaryInventiva and Harrow tied by winning 7 of the 14 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$314.34M$2.93B$5.51B$9.40BDividend YieldN/A2.48%4.00%4.04%P/E RatioN/A19.8828.2019.77Price / Sales31.59229.13413.3488.91Price / CashN/A40.8024.9928.17Price / Book-2.727.668.155.69Net Income-$199.34M-$55.16M$3.25B$257.97M7 Day Performance-5.03%1.10%0.42%1.92%1 Month Performance-0.12%13.14%7.75%12.82%1 Year Performance26.38%3.51%33.65%19.22% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva2.7218 of 5 stars$3.29+0.8%$10.40+216.5%+26.4%$314.34M$9.95M0.00100HROWHarrow2.437 of 5 stars$35.62+2.0%$63.83+79.2%+43.5%$1.31B$199.61M-63.61180Trending NewsPAHCPhibro Animal Health4.0475 of 5 stars$31.54+2.4%$24.40-22.6%+57.8%$1.28B$1.02B40.441,940Positive NewsABCLAbCellera Biologics2.4996 of 5 stars$4.24+5.7%$8.75+106.4%+50.8%$1.27B$28.83M-7.57500High Trading VolumeCOGTCogent Biosciences3.5496 of 5 stars$11.09+1.0%$18.00+62.3%+45.1%$1.26BN/A-6.0380Trending NewsAnalyst ForecastGap UpHigh Trading VolumePHVSPharvaris1.4387 of 5 stars$23.80-5.3%$36.20+52.1%+26.6%$1.24BN/A-7.9130Gap UpHigh Trading VolumeNTLAIntellia Therapeutics4.311 of 5 stars$11.95+3.6%$33.37+179.2%-51.9%$1.24B$57.88M-2.28600Analyst RevisionCVACCureVac4.0672 of 5 stars$5.46flat$6.83+25.2%+46.9%$1.22B$579.18M5.93880AUPHAurinia Pharmaceuticals3.1175 of 5 stars$9.04+2.7%$11.50+27.2%+55.2%$1.22B$235.13M32.29300Positive NewsWVEWAVE Life Sciences4.6605 of 5 stars$7.84+1.8%$20.50+161.5%+42.8%$1.22B$108.30M-9.33240CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies HROW Competitors PAHC Competitors ABCL Competitors COGT Competitors PHVS Competitors NTLA Competitors CVAC Competitors AUPH Competitors WVE Competitors CALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
